Optimal Therapeutics Newsroom - Profile and News Archive

Optimal Therapeutics | Optimal Therapeutics, Urban Biologics, Camille Westhoff, Nextrutine, Fematril, Viastat, Zalestra, Zyroxin, Neurovar, Immunitril, Phosoplex, Bone & Joint, Joint Health, BioCell Collagen, Cox II, Cox II Inhibitors, Collagen, Healthy Joints, Joint Relief, Pain Relief, New Jersey Newswire, news

Engage with Optimal Therapeutics


RSS News Feed for Optimal Therapeutics

Press Releases from Optimal Therapeutics :

Optimal Therapeutics Announces the Signing of a Licensing Agreement with Kwowa Hakko USA for the Ingredient Cognizin(R) to be Included in Their Brain Function Formula Neurovar

CEDAR GROVE, NJ /Send2Press Newswire/ — Optimal Therapeutics announces the signing of a licensing agreement with Kwowa Hakko USA for the ingredient Cognizin(R) to be included in their brain function formula Neurovar.

New Jersey Based Optimal Therapeutics Announces the Signing of Licensing Agreement for the Trademarked Ingredient Nextrutine(R) in Their Phosoplex Joint Formulation

CEDAR GROVE, NJ /Send2Press Newswire/ — New Jersey based Optimal Therapeutics announces the signings of licensing agreements for trademarked ingredients in their Phosoplex Joint Formulation. BioCell Collagen II from BioCell Technology LLC and Nextrutine(R) from Next Pharmaceutical are exciting ingredient additions to an already potent joint health formula.